Twist BioscienceTWST
TWST
About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Employees: 923
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
196% more call options, than puts
Call options by funds: $5.99M | Put options by funds: $2.02M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
9% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 82
3% more capital invested
Capital invested by funds: $2.98B [Q3] → $3.08B (+$104M) [Q4]
0% more funds holding
Funds holding: 243 [Q3] → 244 (+1) [Q4]
1.01% less ownership
Funds ownership: 112.47% [Q3] → 111.45% (-1.01%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
4%
upside
Avg. target
$50
31%
upside
High target
$62
62%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target | 17%upside $45 | Overweight Maintained | 10 Apr 2025 |
Scotiabank Sung Ji Nam 8% 1-year accuracy 2 / 24 met price target | 62%upside $62 | Sector Outperform Maintained | 4 Feb 2025 |
JP Morgan Rachel Vatnsdal 69% 1-year accuracy 11 / 16 met price target | 4%upside $40 | Underweight Maintained | 4 Feb 2025 |
Baird Catherine Ramsey 39% 1-year accuracy 7 / 18 met price target | 41%upside $54 | Outperform Maintained | 4 Feb 2025 |
Financial journalist opinion
Neutral
Business Wire
6 days ago
Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System.
Neutral
Business Wire
1 month ago
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software.
Positive
Zacks Investment Research
1 month ago
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Positive
Zacks Investment Research
1 month ago
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
1 month ago
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. “At Twist, we recognize the increasing challenge within colleges, universities and research ins.
Neutral
Business Wire
2 months ago
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 in Boston, MA.
Neutral
Business Wire
2 months ago
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 123,024 equity awards, consisting of 72,394 restricted stock units (“RSUs”) and up to 50,630 performance stock units (“PSUs”), to 32 recently hired individuals, in each case as a.
Positive
Zacks Investment Research
2 months ago
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Finbold
2 months ago
Cathie Wood dumped Palantir to buy these biotech stocks
Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.
Negative
Seeking Alpha
2 months ago
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Charts implemented using Lightweight Charts™